Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.

导出原文传递

翻译打印收藏纠错

作者： Esther,Drill ^[1] ; Annie,Qiu ^[2] ; Sheila,Shapouri ^[3] ; Tu My,To ^[3] ; Arliene,Ravelo ^[3] ; Jake,Schade ^[2] ; Keith,Dawson ^[4] ; Matthew,Matasar ^[2]

作者单位： Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[1] Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[2] Evidence for Access, Genentech, Inc, South San Francisco, CA, USA. ^[3] US Medical Affairs, Genentech, Inc, South San Francisco, CA, USA. ^[4]

关键词 Chronic lymphocytic leukemia diffuse large B-cell lymphoma efficiency follicular lymphoma rituximab subcutaneous

主题词人类(Humans);免疫因子类(Immunologic Factors);注射, 皮下(Injections, Subcutaneous);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);淋巴瘤, 滤泡性(Lymphoma, Follicular);病人医疗护理(Patient Care);回顾性研究(Retrospective Studies)

DOI 10.46883/2021.25920935

PMID 35089000

发布时间 2022-02-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交